A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice.

Oncotarget 2016 Oct;7(43):70462-70474

Department of Biochemistry and University of Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA.

While decades of research have identified molecular pathways inducing and promoting stages of prostate cancer malignancy, studies addressing dynamic changes of cancer-related regulatory factors in a prostate tumor progression model are limited. Using the TRAMP mouse model of human prostate cancer, we address mechanisms of deregulation for the cancer-associated transcription factors, Runx1 and Runx2 by identifying microRNAs with reciprocal expression changes at six time points during 33 weeks of tumorigenesis. We molecularly define transition stages from PIN lesions to hyperplasia/neoplasia and progression to adenocarcinoma by temporal changes in expression of human prostate cancer markers, including the androgen receptor and tumor suppressors, Nkx3.1 and PTEN. Concomitant activation of PTEN, AR, and Runx factors occurs at early stages. At late stages, PTEN and AR are downregulated, while Runx1 and Runx2 remain elevated. Loss of Runx-targeting microRNAs, miR-23b-5p, miR-139-5p, miR-205-5p, miR-221-3p, miR-375-3p, miR-382-5p, and miR-384-5p, contribute to aberrant Runx expression in prostate tumors. Our studies reveal a Runx/miRNA interaction axis centered on PTEN-PI3K-AKT signaling. This regulatory network translates to mechanistic understanding of prostate tumorigenesis that can be developed for diagnosis and directed therapy.

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.11992DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342565PMC
October 2016
11 Reads

Publication Analysis

Top Keywords

prostate cancer
12
prostate tumor
8
tumor progression
8
human prostate
8
runx1 runx2
8
prostate
7
nkx31 pten
4
suppressors nkx31
4
tumor suppressors
4
markers including
4
including androgen
4
androgen receptor
4
receptor tumor
4
pten concomitant
4
pten runx
4
early stages
4
stages late
4
late stages
4
occurs early
4
factors occurs
4

Similar Publications